Publications by authors named "Milena Aksentijevich"
Article Synopsis
- Lipid-rich necrotic core (LRNC) is a dangerous type of plaque linked to higher cardiovascular risks, particularly in psoriasis patients, who are already at increased risk for heart issues.
- A study involved 209 psoriasis patients who used a special imaging technique to examine LRNC before and after a year of biologic therapy.
- Results showed that patients on biologic therapy had a significant reduction in LRNC, while those not on therapy showed no significant change, indicating that biologic treatment can positively affect heart health in psoriasis patients.
Background: Inflammation plays a major role in the development and progression of cardiovascular disease (CVD) morbidity and mortality. The well-established relationship between periodontal disease (PD) and CVD may be causal. Left untreated, PD can lead to high systemic inflammation, thus contributing to inflammatory CVD, such as atherosclerosis.
View Article and Find Full Text PDFChronic inflammation in humans is associated with accelerated development of cardiometabolic diseases such as myocardial infarction, stroke, and diabetes. Strong evidence from animal models and human interventional trials including CANTOS (The Canakinumab Anti-inflammatory Thrombosis Outcome Study) suggests that targeting residual systemic inflammation in humans may impart a benefit in reducing cardiometabolic diseases. Diseases associated with heightened immune-activation and systemic inflammation including psoriasis, rheumatoid arthritis, systemic lupus erythematosus, and human immunodeficiency virus infection are associated with upwards of two to seven-fold risk of future adverse cardiac events even when adjusted for traditional risk factors.
View Article and Find Full Text PDFArticle Synopsis
- Psoriasis is linked to an increased risk of coronary artery disease, potentially through elevated levels of soluble LOX-1, a receptor that interacts with oxidized lipoproteins.
- A cohort study at the National Institutes of Health involved 175 psoriasis patients to analyze the relationship between soluble LOX-1 and noncalcified coronary burden over time.
- Results showed that psoriasis patients had higher levels of soluble LOX-1 compared to matched controls, suggesting a potential connection to cardiovascular risk.
Article Synopsis
- Psoriasis patients face a higher risk of heart attacks and increased noncalcified coronary burden, which can be evaluated using coronary computed tomography angiography (CCTA).
- This study utilized machine learning algorithms on data from 263 patients to identify key predictors of noncalcified coronary burden, focusing on variables related to body composition and inflammation.
- The top predictors included factors like body mass index and levels of certain lipoproteins, suggesting that addressing obesity, dyslipidemia, and inflammation is vital in managing psoriasis-related health risks.
Article Synopsis
- The study investigates how inflammation from psoriasis, a chronic inflammatory disease, affects cardiovascular disease (CVD) by looking at aortic vascular uptake and aortic wall thickness in patients.
- Researchers found that the severity of psoriasis correlates with greater aortic wall thickness and uptake of a specific imaging marker called 18F-FDG.
- After a year of psoriasis treatment, participants exhibited reductions in both aortic vascular uptake and wall thickness, highlighting potential links between inflammation and early signs of vascular disease.
Article Synopsis
- Psoriasis is a chronic skin disease linked to cardiovascular issues, and while biologic therapies are beneficial for the skin, their impact on coronary inflammation is not fully understood.
- This study examined the effects of biologic therapy on coronary inflammation in psoriasis patients by using a measurement technique called perivascular fat attenuation index (FAI) during coronary CT angiography.
- Out of 134 patients, those who received biologic treatment showed a significant decrease in FAI compared to the control group, suggesting that biologic therapies may help reduce coronary inflammation in psoriasis patients.